Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 1.43 is in line with its 5-year average of 1.50, around the middle of its 5-year range (1.04–2.23).
As of the fiscal period ended Tuesday, June 30, 2026. 13.97% below its 12-month average of 1.66.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.43.
CURRENT RATIO
1.43
CURRENT RATIO AVG TTM
1.66
CURRENT RATIO AVG 3Y
1.48
CURRENT RATIO AVG 5Y
1.50
CURRENT RATIO AVG 10Y
1.75
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-13.97%
CURRENT VS 3Y AVG
-3.85%
CURRENT VS 5Y AVG
-4.77%
CURRENT VS 10Y AVG
-18.45%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.08
median of 454 covered companies
CURRENT VS SECTOR MEDIAN
-53.59%
vs the sector median at left
Akebia Therapeutics, Inc.
Market Cap
$244.25M
Current Ratio
1.43
TTM Avg
1.66
3Y Avg
1.48
5Y Avg
1.50
Market Cap
$245.65M
Current Ratio
0.10
TTM Avg
1.46
3Y Avg
1.56
5Y Avg
2.73
Market Cap
$248.21M
Current Ratio
1.54
TTM Avg
1.17
3Y Avg
19.33
5Y Avg
29.22
Market Cap
$251.64M
Current Ratio
4.70
TTM Avg
7.13
3Y Avg
7.51
5Y Avg
5.68
Market Cap
$259.30M
Current Ratio
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $244.25M | 1.43 | 1.66 | 1.48 | 1.50 |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | 0.10 | 1.46 | 1.56 | 2.73 |
| InflaRx N.V. (IFRX)vs › | $247.45M | 8.22 | 4.59 | 5.79 | 6.14 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | 1.54 | 1.17 | 19.33 | 29.22 |
| High Tide Inc. (HITI)vs › | $239.89M | 1.50 | 1.39 | 1.25 | 1.14 |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | 17.19 | 13.55 | 8.08 | 8.08 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | 4.70 | 7.13 | 7.51 | 5.68 |
| Biodesix, Inc. (BDSX)vs › | $236.56M | 2.85 | 2.31 | 2.04 | 2.06 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | 16.00 | 13.11 | 8.33 | 7.81 |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | 4.48 | 4.80 | 5.23 | 5.23 |
Current Ratio
1.43
Quick Ratio
1.35
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 1.43 |
| 2026-03-31 | 1.40 |
| 2025-12-31 | 1.55 |
| 2025-09-30 | 1.94 |
| 2025-06-30 | 1.98 |
| 2025-03-31 | 2.23 |
| 2024-12-31 | 1.41 |
| 2024-09-30 | 1.52 |
| 2024-06-30 | 1.04 |
| 2024-03-31 | 1.70 |
| 2023-12-31 | 1.18 |
| 2023-09-30 | 1.38 |
| 2023-06-30 | 1.28 |
| 2023-03-31 | 1.46 |
| 2022-12-31 | 1.43 |
| 2022-09-30 | 1.26 |
| 2022-06-30 | 1.30 |
| 2022-03-31 | 1.19 |
| 2021-12-31 | 1.04 |
| 2021-09-30 | 1.74 |
| 2021-06-30 | 2.00 |
| 2021-03-31 | 2.11 |
| 2020-12-31 | 1.98 |
| 2020-09-30 | 2.15 |
| 2020-06-30 | 2.29 |
| 2020-03-31 | 1.59 |
| 2019-12-31 | 1.49 |
| 2019-09-30 | 1.34 |
| 2019-06-30 | 1.70 |
| 2019-03-31 | 1.71 |
| 2018-12-31 | 1.76 |
| 2018-09-30 | 2.24 |
| 2018-06-30 | 2.48 |
| 2018-03-31 | 2.89 |
| 2017-12-31 | 2.48 |
| 2017-09-30 | 2.21 |
| 2017-06-30 | 1.83 |
| 2017-03-31 | 1.91 |
| 2016-12-31 | 2.59 |
| 2016-09-30 | 6.32 |
| 2016-06-30 | 9.20 |
| 2016-03-31 | 16.37 |
| 2015-12-31 | 11.88 |
| 2015-09-30 | 11.21 |
| 2015-06-30 | 26.25 |
| 2015-03-31 | 11.62 |
| 2014-12-31 | 16.05 |
| 2014-09-30 | 18.37 |
| 2014-06-30 | 26.43 |
| 2014-03-31 | 21.84 |
| 2013-12-31 | 8.57 |
| 2013-09-30 | 13.27 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
| 2012-12-31 | 2.92 |
